Phaseline

Companies › Mapi Pharma

Mapi Pharma: clinical trials, targets and expected readouts

2 active drug programs in 5 registered trials: 5 Phase 1; Psychiatry, Metabolic and endocrine; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Cariprazine
Dopamine D3 receptor modulator; Dopamine D2 receptor modulator
DRD3, DRD2Phase 1SchizophreniaDec 2026
SG Depot 2 mg
GLP-1 receptor agonist
GLP1RPhase 1Diabete Type 2May 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07185815CariprazinePhase 1SchizophreniaPsychiatryDec 2026
NCT07563699SG Depot 2 mgPhase 1Diabete Type 2Metabolic and endocrineMay 2028
NCT07563699SG Depot 2 mgPhase 1Diabete Type 2Metabolic and endocrineMay 2028
NCT07563699SG Depot 2 mgPhase 1Diabete Type 2Metabolic and endocrineMay 2028
NCT07563699SG Depot 2 mgPhase 1Diabete Type 2Metabolic and endocrineMay 2028

From the company's SEC filings

Complete response letters from FDA

Targets

DRD3 (1) DRD2 (1) GLP1R (1)

Companies with the same targets

Eli Lilly Novo Nordisk Roche Hangzhou Sciwind Biosciences LB Pharmaceuticals Gedeon Richter Serina Therapeutics Boryung Pharmaceutical Anxo Pharmaceutical AbbVie

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.